Related Experiment Video
Updated: Apr 20, 2026
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck
Anthony C Nichols1, Morgan Black, John Yoo
1Department of Otolaryngology Head & Neck Surgery, Western University, London, Ontario, Canada. anthony.nichols@lhsc.on.ca.
Background:
There is an urgent need for better therapeutics in head and neck squamous cell cancer (HNSCC) to improve survival and decrease treatment morbidity. Recent advances in high-throughput drug screening techniques and next-generation sequencing have identified new therapeutic targets in other cancer types, but an HNSCC-specific study has not yet been carried out. We have exploited data from two large-scale cell line projects to clearly describe the mutational and copy number status of HNSCC cell lines and identify candidate drugs with elevated efficacy in HNSCC.
Methods:
The genetic landscape of 42 HNSCC cell lines including mutational and copy number data from studies by Garnett et al., and Barretina et al., were analyzed. Data from Garnett et al. was interrogated for relationships between HNSCC cells versus the entire cell line pool using one- and two-way analyses of variance (ANOVAs). As only seven HNSCC cell lines were tested with drugs by Barretina et al., a similar analysis was not carried out.
Results:
Recurrent mutations in human papillomavirus (HPV)-negative patient tumors were confirmed in HNSCC cell lines, however additional, recurrent, cell line-specific mutations were identified. Four drugs, Bosutinib, Docetaxel, BIBW2992, and Gefitinib, were found via multiple-test corrected ANOVA to have lower IC50 values, suggesting higher drug sensitivity, in HNSCC lines versus non-HNSCC lines. Furthermore, the PI3K inhibitor AZD6482 demonstrated significantly higher activity (as measured by the IC50) in HNSCC cell lines harbouring PIK3CA mutations versus those that did not.
Conclusion:
HNSCC-specific reanalysis of large-scale drug screening studies has identified candidate drugs that may be of therapeutic benefit and provided insights into strategies to target PIK3CA mutant tumors. PIK3CA mutations may represent a predictive biomarker for response to PI3K inhibitors. A large-scale study focused on HNSCC cell lines and including HPV-positive lines is necessary and has the potential to accelerate the development of improved therapeutics for patients suffering with head and neck cancer. This strategy can potentially be used as a template for drug discovery in any cancer type.
Insights
New analysis of head and neck squamous cell cancer (HNSCC) cell lines identified promising drugs like Bosutinib and Gefitinib. PIK3CA mutations may predict response to PI3K inhibitors, offering targeted therapy for HNSCC patients.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Head and neck squamous cell cancer (HNSCC) requires improved therapeutics to enhance survival and reduce treatment side effects.
- Recent advancements in drug screening and sequencing offer new therapeutic targets, but HNSCC-specific studies are lacking.
- This study analyzes HNSCC cell line data to identify potential drug candidates and therapeutic strategies.
Purpose of the Study:
- To characterize the mutational and copy number status of HNSCC cell lines.
- To identify drugs with enhanced efficacy in HNSCC cell lines through large-scale screening data analysis.
- To explore PIK3CA mutations as potential biomarkers for targeted therapies.
Main Methods:
- Analysis of genetic data (mutations and copy number) from 42 HNSCC cell lines.
- Utilized data from Garnett et al. and Barretina et al. cell line projects.
- Applied one- and two-way analyses of variance (ANOVAs) to identify drug-HNSCC relationships.
Main Results:
- Confirmed known mutations in HPV-negative HNSCC and identified novel cell line-specific mutations.
- Identified four drugs (Bosutinib, Docetaxel, BIBW2992, Gefitinib) with significantly lower IC50 values in HNSCC lines.
- The PI3K inhibitor AZD6482 showed higher activity in HNSCC lines with PIK3CA mutations.
Conclusions:
- Reanalysis of drug screening data in HNSCC cell lines identified potential therapeutic agents.
- PIK3CA mutations may serve as predictive biomarkers for response to PI3K inhibitors in HNSCC.
- Further large-scale studies, including HPV-positive lines, are needed to accelerate HNSCC therapeutic development.
